Full Text View
Tabular View
No Study Results Posted
Related Studies
Hormone and Information Processing Study (HIP)
This study is currently recruiting participants.
Study NCT00539305   Information provided by National Institute on Aging (NIA)
First Received: October 3, 2007   Last Updated: February 24, 2009   History of Changes

October 3, 2007
February 24, 2009
April 2007
March 2010   (final data collection date for primary outcome measure)
  • Behavioral & Mood measure: Profile of Mood States (POMS) [ Time Frame: Baseline, 3 and 6 months ] [ Designated as safety issue: No ]
  • Cognitive changes measured by Neuropsychological tests: ADAS-Cog (MCI version), Route Test, Paragraph recall [ Time Frame: Baseline, 3 and 6 months ] [ Designated as safety issue: No ]
  • Cerebrospinal Fluid (CSF) [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
  • APOE genotyping [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Behavioral & Mood measure: Profile of Mood States (POMS) [ Time Frame: Baseline, 3 and 6 months ]
  • Cognitive changes measured by Neuropsychological tests: ADAS-Cog (MCI version), Route Test, Paragraph recall [ Time Frame: Baseline, 3 and 6 months ]
  • Cerebrospinal Fluid (CSF) [ Time Frame: Baseline and 6 months ]
  • APOE genotyping [ Time Frame: Baseline ]
Complete list of historical versions of study NCT00539305 on ClinicalTrials.gov Archive Site
 
 
 
Hormone and Information Processing Study
Testosterone Supplementation in Men With MCI

The purpose of this study is to examine the effects of testosterone (T) replacement on changes in thinking and memory, as well as mood in older men with mild cognitive impairment (MCI) and low T levels. The study will also examine whether taking testosterone has effects on biological markers related to Alzheimer's disease.

Natural age related declines in testosterone (T) are associated with decreases in cognitive abilities independent of health status. Low T levels over time are associated with increased risk for developing Alzheimer's disease (AD). These findings suggest that men with low T levels are most at risk for age-related cognitive decline and AD and therefore most likely to benefit from T supplementation to prevent the development of AD or age-associated cognitive decline. The current study will assess cognition, mood, and cerebral spinal fluid (CSF) biomarker response to T supplementation in older men with mild cognitive impairment (MCI) and low T levels.

Participants will be randomized to either receive T treatment or a placebo for six months. Participants will come in for about five visits within the span of six months where they will complete cognitive & memory tests, fill out mood questionnaires, and have their blood drawn to monitor the medication level. A sample of blood will also be taken at one visit to test for apolipoprotein E (APOE), which is a genetic risk factor associated with AD. Participants will have the option to get a spinal tap in order to measure biological markers associated with Alzheimer's disease including beta-amyloid 1-40, 42, total-tau, and phosphorylated-tau-181-231. This will require an additional two visits.

Phase III
Interventional
Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
  • Mild Cognitive Impairment
  • Alzheimer's Disease
  • Drug: testosterone gel
  • Drug: placebo gel
Experimental: Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
60
December 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male 60-90 years of age
  • Diagnosis of mild cognitive impairment (MCI)
  • Low testosterone level
  • Primary language is English
  • Availability of an informant who knows the participant well enough to answer questions
  • Stable medications for the previous 3 months
  • Normal complete blood count (CBC), calcium, albumin, TSH, and no clinically significant blood chemistry
  • American Urological Association (AUA) symptom score less than or equal to 19
  • Body Mass Index (BMI) less than 33 and stable weight in the previous year

Exclusion Criteria:

  • Prior history of prostate cancer or prostate specific antigen level greater than 4.0ng/ml
  • Peripheral or vascular disease
  • Significant history of alcohol abuse, current alcohol abuse (more than 2 drinks per day), or other substance abuse
  • History of severe head injury (with loss of consciousness greater than 30 minutes)
  • Significant neurological illness, such as Parkinson's disease, seizure disorder, multiple sclerosis, major stoke
  • Smokes cigarettes
  • Major psychiatric illness, such as schizophrenia or bipolar disorder

Prohibited Medications:

  • Anti-convulsants
  • Anti-psychotics
  • Sedating antihistamines
  • Sedative/hypnotics
  • Benzodiazepines
  • Hormone or testosterone regimens
  • GNRH antagonists
  • Flutamide
  • Anti-depressants and/or anti-cholinesterase inhibitors, but acceptable if on stable dose for 3 months or more
Male
60 Years to 90 Years
No
Contact: Christina Bradic 206-277-1155 cb80@u.washington.edu
Contact: Gareth Holman 206-277-5055 gholman@u.washington.edu
United States
 
NCT00539305
Monique Cherrier, PhD, University of Washington
IA0124, 1R01AG027156-01 A2
National Institute on Aging (NIA)
Solvay Pharmaceuticals
Principal Investigator: Monique Cherrier, PhD University of Washington
National Institute on Aging (NIA)
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP